Cargando…

SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?

Detalles Bibliográficos
Autores principales:	Guisado Hernández, Paloma, Blanco Lobo, Pilar, Villaoslada, Isabel, de Felipe, Beatriz, Lucena, José M., Martín Gutierrez, Guillermo, Castro, María José, Gutiérrez Valencia, Alicia, Sánchez Codez, María Isabel, Gaboli, Mirella, Neth, Olaf, Olbrich, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189704/ https://www.ncbi.nlm.nih.gov/pubmed/34109505 http://dx.doi.org/10.1007/s10875-021-01081-9

Ejemplares similares

Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations—10 Children and Review of the Literature
por: Deyà-Martínez, Angela, et al.
Publicado: (2022)

Ruxolitinib Controls Lymphoproliferation and Diabetes in a STAT3-GOF Patient
por: Wegehaupt, Oliver, et al.
Publicado: (2020)

STAT1 Gain-of-Function and Hidradenitis Suppurativa Successfully Managed with Baricitinib
por: Olbrich, Peter, et al.
Publicado: (2023)

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient
por: Thalhammer, Julian, et al.
Publicado: (2021)

Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients
por: Bloomfield, Marketa, et al.
Publicado: (2021)

The Irrationality of GOF Avian Influenza Virus Research
por: Wain-Hobson, Simon
Publicado: (2014)

Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection
por: Sanchez-Codez, Maria Isabel, et al.
Publicado: (2021)

GOF Mutant p53 in Cancers: A Therapeutic Challenge
por: Dolma, Lobsang, et al.
Publicado: (2022)

Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
por: Roszkowska, Katarzyna A., et al.
Publicado: (2022)

Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
por: Schulz-Heddergott, Ramona, et al.
Publicado: (2018)

Clinical presentation and early predictors for poor outcomes in pediatric myocarditis: A retrospective study
por: Rodriguez-Gonzalez, Moises, et al.
Publicado: (2019)

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019)

Statistical power estimation dataset for external validation GoF tests on EVT distribution
por: Reghenzani, Federico, et al.
Publicado: (2019)

NLRC4 GOF Mutations, a Challenging Diagnosis from Neonatal Age to Adulthood
por: Bardet, Juliette, et al.
Publicado: (2021)

Single-cell RNA sequencing combined with whole exome sequencing reveals the landscape of the immune pathogenic response to chronic mucocutaneous candidiasis with STAT1 GOF mutation
por: Lu, Xiaodi, et al.
Publicado: (2022)

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
por: Goker Bagca, Bakiye, et al.
Publicado: (2020)

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
por: Marcuzzi, Annalisa, et al.
Publicado: (2022)

Piomiositis glútea con absceso del obturador interno en contexto de infección aguda por Bartonella henselae
por: Sánchez-Códez, María Isabel, et al.
Publicado: (2021)

Secondary C1q Deficiency in Activated PI3Kδ Syndrome Type 2
por: Hong, Ying, et al.
Publicado: (2019)

mBio Addresses the Pause in Gain-of-Function (GOF) Experiments Involving Pathogens with Pandemic Potential (PPP)
por: Casadevall, Arturo, et al.
Publicado: (2014)

Vagueness and Costs of the Pause on Gain-of-Function (GOF) Experiments on Pathogens with Pandemic Potential, Including Influenza Virus
por: Imperiale, Michael J., et al.
Publicado: (2014)

Gramnegativos infrecuentes como agentes etiológicos de infecciones nosocomiales en una Unidad de Cuidados Intensivos Neonatales
por: Sánchez-Códez, María Isabel, et al.
Publicado: (2018)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Predictors of Treatment Outcomes in Geriatric Patients With Odontoid Fractures: AOSpine North America Multi-Centre Prospective GOF Study
por: Fehlings, Michael G., et al.
Publicado: (2013)

The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib
por: Tremblay, Douglas, et al.
Publicado: (2019)

Ruxolitinib: Thrombocytopenia following compassionate use of ruxolitinib: 2 case reports
Publicado: (2022)

Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: a new promise in cancer therapy
por: Alexandrova, Evguenia M, et al.
Publicado: (2017)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
por: Escamilla Gómez, Virginia, et al.
Publicado: (2019)

Transcriptome profiling identifies genes and pathways deregulated upon floxuridine treatment in colorectal cancer cells harboring GOF mutant p53
por: Datta, Arindam, et al.
Publicado: (2016)

JAK/STAT Signaling and Cervical Cancer: From the Cell Surface to the Nucleus
por: Valle-Mendiola, Arturo, et al.
Publicado: (2023)

Role of the JAK/STAT Pathway in Cervical Cancer: Its Relationship with HPV E6/E7 Oncoproteins
por: Gutiérrez-Hoya, Adriana, et al.
Publicado: (2020)

Ruxolitinib in severe COVID-19 Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome
por: Iastrebner, Marcelo, et al.
Publicado: (2021)

Efficacy of Ruxolitinib Therapy in a Patient With Severe Enterocolitis Associated With a STAT3 Gain-of-Function Mutation
por: Parlato, Marianna, et al.
Publicado: (2019)

Unexpected Neurological Symptoms of Ruxolitinib: A Case Report
por: Furia, Francesca, et al.
Publicado: (2020)

À propos du COVD-19 : note de l’éditeur et des rédacteurs en chef de la revue GOFS
Publicado: (2020)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

Coccidioidomycosis in Patients Treated With Ruxolitinib
por: Kusne, Yael, et al.
Publicado: (2020)

Ruxolitinib for the Treatment of Essential Thrombocythemia
por: Gunawan, Arief, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nn6malc8hif9r5kl4qmgedn9qi